BTIG downgraded Vericel (VCEL) to Neutral from Buy without a price target The stock is down 42% this year following two “softer” quarters, the analyst tells investors in a research note. BTIG’s survey of MACI users suggests limited increases in both biopsy growth and conversion from the MACI Arthro launch to drive estimates higher. The firm points out that 60% of surgeons surveyed expect no change to MACI volumes despite Arthro as an option now.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCEL:
- Vericel’s Phase 3 Study on MACI: A Potential Game-Changer in Cartilage Repair
- Vericel’s MACI Arthro: Driving Over 20% Growth with Market Expansion and Innovation
- Vericel’s Growth Potential and Attractive Valuation Justify Buy Rating Despite 2Q25 Sales Miss
- Vericel Corporation Reports Strong Q2 2025 Earnings
- Vericel price target lowered to $58 from $61 at Canaccord